These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32188623)

  • 1. Type I IFN, Ly6C
    Dyevoich AM; Haas KM
    Mol Cancer Ther; 2020 Jun; 19(6):1232-1242. PubMed ID: 32188623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of B-1 Cells Promotes Tumor Cell Killing in the Peritoneal Cavity.
    Haro MA; Dyevoich AM; Phipps JP; Haas KM
    Cancer Res; 2019 Jan; 79(1):159-170. PubMed ID: 30224373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A TLR4-TRIF-dependent signaling pathway is required for protective natural tumor-reactive IgM production by B1 cells.
    Dyevoich AM; Disher NS; Haro MA; Haas KM
    Cancer Immunol Immunother; 2020 Oct; 69(10):2113-2124. PubMed ID: 32448982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine.
    Hovav AH; Fishman Y; Bercovier H
    Infect Immun; 2005 Jan; 73(1):250-7. PubMed ID: 15618161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
    Ravindran R; Maji M; Ali N
    Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type I IFN Receptor Signaling on B Cells Promotes Antibody Responses to Polysaccharide Antigens.
    Spurrier MA; Jennings-Gee JE; Haas KM
    J Immunol; 2023 Jan; 210(2):148-157. PubMed ID: 36458995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type I interferon signaling regulates Ly6C(hi) monocytes and neutrophils during acute viral pneumonia in mice.
    Seo SU; Kwon HJ; Ko HJ; Byun YH; Seong BL; Uematsu S; Akira S; Kweon MN
    PLoS Pathog; 2011 Feb; 7(2):e1001304. PubMed ID: 21383977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monophosphoryl lipid A (MPL) upregulates major histocompatibility complex (MHC) class I expression by increasing interferon-gamma (IFN-gamma).
    Cho CH; Lee BK; Kwak SM; Kim JD
    Yonsei Med J; 1999 Feb; 40(1):20-5. PubMed ID: 10198602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation.
    Müller E; Speth M; Christopoulos PF; Lunde A; Avdagic A; Øynebråten I; Corthay A
    Front Immunol; 2018; 9():2520. PubMed ID: 30450098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the adjuvant MPL + TDM on tumor challenge in the B16 mouse melanoma model.
    Price JA; McGee JM; Patten MR; Snyder D
    Int J Immunopharmacol; 1996 Feb; 18(2):163-5. PubMed ID: 8799366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine.
    Gableh F; Saeidi M; Hemati S; Hamdi K; Soleimanjahi H; Gorji A; Ghaemi A
    J Biomed Sci; 2016 Jan; 23():16. PubMed ID: 26811064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of vizantin, a safe immunostimulant, based on the structure-activity relationship of trehalose-6,6'-dicorynomycolate.
    Yamamoto H; Oda M; Nakano M; Watanabe N; Yabiku K; Shibutani M; Inoue M; Imagawa H; Nagahama M; Himeno S; Setsu K; Sakurai J; Nishizawa M
    J Med Chem; 2013 Jan; 56(1):381-5. PubMed ID: 23210481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of NK1.1(+) T cells as well as NK cells against intraperitoneal tumors in mice.
    Kawamura T; Seki S; Takeda K; Narita J; Ebe Y; Naito M; Hiraide H; Abo T
    Cell Immunol; 1999 May; 193(2):219-25. PubMed ID: 10222065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective adjuvants for the induction of antigen-specific delayed-type hypersensitivity.
    Baldridge JR; Ward JR
    Vaccine; 1997 Mar; 15(4):395-401. PubMed ID: 9141210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monophosphoryl lipid A-induced immune enhancement of Brucella abortus salt-extractable protein and lipopolysaccharide vaccines in BALB/c mice.
    Tabatabai LB; Pugh GW; Stevens MG; Phillips M; McDonald TJ
    Am J Vet Res; 1992 Oct; 53(10):1900-7. PubMed ID: 1456539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant cationic liposomes presenting MPL and IL-12 induce cell death, suppress tumor growth, and alter the cellular phenotype of tumors in a murine model of breast cancer.
    Meraz IM; Savage DJ; Segura-Ibarra V; Li J; Rhudy J; Gu J; Serda RE
    Mol Pharm; 2014 Oct; 11(10):3484-91. PubMed ID: 25179345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toll-like receptor 4 and Toll-IL-1 receptor domain-containing adapter protein (TIRAP)/myeloid differentiation protein 88 adapter-like (Mal) contribute to maximal IL-6 expression in macrophages.
    Schilling D; Thomas K; Nixdorff K; Vogel SN; Fenton MJ
    J Immunol; 2002 Nov; 169(10):5874-80. PubMed ID: 12421970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potent adjuvant monophosphoryl lipid A triggers various immune responses, but not secretion of IL-1beta or activation of caspase-1.
    Okemoto K; Kawasaki K; Hanada K; Miura M; Nishijima M
    J Immunol; 2006 Jan; 176(2):1203-8. PubMed ID: 16394010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan.
    Vono M; Eberhardt CS; Mohr E; Auderset F; Christensen D; Schmolke M; Coler R; Meinke A; Andersen P; Lambert PH; Mastelic-Gavillet B; Siegrist CA
    Front Immunol; 2018; 9():381. PubMed ID: 29541075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. M-cell targeted polymeric lipid nanoparticles containing a Toll-like receptor agonist to boost oral immunity.
    Ma T; Wang L; Yang T; Ma G; Wang S
    Int J Pharm; 2014 Oct; 473(1-2):296-303. PubMed ID: 24984067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.